Skip to content

Zymeworks ZYME Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Septerna, Inc. logo
Septerna, Inc.SEPN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's operating lease right-of-use assets in other assets?
Zymeworks (ZYME) reported operating lease right-of-use assets in other assets of $14.02M in Q1 2026.
How has Zymeworks's operating lease right-of-use assets in other assets changed year-over-year?
Zymeworks's operating lease right-of-use assets in other assets decreased by 16.2% year-over-year, from $16.72M to $14.02M.
What is the long-term trend for Zymeworks's operating lease right-of-use assets in other assets?
Over 4 years (2021 to 2025), Zymeworks's operating lease right-of-use assets in other assets has grown at a -12.6% compound annual growth rate (CAGR), from $26.99M to $15.72M.